BMC
Gastroenterology

RESEARCH ARTICLE

Open Access

A comparison of four fibrosis indexes in chronic HCV: Development of new fibrosis-cirrhosis index (FCI)

Waqar Ahmad[1†], Bushra Ijaz[1†], Fouzia T Javed[2], Sana Gull[1], Humera Kausar[1], Muhammad T Sarwar[1], Sultan Asad[1], Imran Shahid[1], Aleena Sumrin[1], Saba Khaliq[1], Shah Jahan[1], Asim Pervaiz[1] and Sajida Hassan[1*]

Abstract

Background: Hepatitis C can lead to liver fibrosis and cirrhosis. We compared readily available non-invasive fibrosis indexes for the fibrosis progression discrimination to find a better combination of existing non-invasive markers.

Methods: We studied 157 HCV infected patients who underwent liver biopsy. In order to differentiate HCV fibrosis progression, readily available AAR, APRI, FI and FIB-4 serum indexes were tested in the patients. We derived a new fibrosis-cirrhosis index (FCI) comprised of ALP, bilirubin, serum albumin and platelet count. FCI = [(ALP × Bilirubin) / (Albumin × Platelet count)].

Results: Already established serum indexes AAR, APRI, FI and FIB-4 were able to stage liver fibrosis with correlation coefficient indexes 0.130, 0.444, 0.578 and 0.494, respectively. Our new fibrosis cirrhosis index FCI significantly correlated with the histological fibrosis stages F0-F1, F2-F3 and F4 (r = 0.818, p < 0.05) with AUROCs 0.932 and 0.996, respectively. The sensitivity and PPV of FCI at a cutoff value < 0.130 for predicting fibrosis stage F0-F1 was 81% and 82%, respectively with AUROC 0.932. Corresponding value of FCI at a cutoff value ≥1.25 for the prediction of cirrhosis was 86% and 100%.

Conclusions: The fibrosis-cirrhosis index (FCI) accurately predicted fibrosis stages in HCV infected patients and seems more efficient than frequently used serum indexes.

Background

Hepatitis C virus (HCV) is considered as a major basis of liver associated diseases throughout the world. More than 350 million people (3% of the world's populations) [1,2] and almost 10 million people in Pakistan are infected with HCV [3]. The genotypes 3a, 3b, 1a and 4a are most prevalent in Pakistan [4]. It is predicted that hepatocellular carcinoma (HCC) develops in 1-4% of HCV infected patients in the first five years following the onset of cirrhosis, but cirrhosis may occur with in the range of 10-50 years [5]. In HCV infected patients, liver biopsy is considered essential to stage liver fibrosis. Procedure of liver biopsy is invasive, expensive and not suitable for all patients. Patients can have severe side effects like pain andharsh complications also leading to death [[1,3] and [5]]. Many previous studies reported that host factors reflect fibrosis development leading to HCC [6,7], so these can be used as non-invasive means to overcome the weaknesses arise from biopsy procedures. Chronic hepatitis C is known as hepatic lesions associated with increased levels of aminotransferases more than 6 months. Moreover, treatment with interferon therapy should be based on the liver fibrosis stage [8]. Various authors tried to find accurate non-invasive markers and develop correlations between the serum aminotransferases levels, hyluronic acid level, collagen level, platelet count and HCV viral titer with fibrosis stages but no clear conclusions were formed. Several scoring systems like AST to ALT ratio (AAR), AST-Platelet ratio (APRI), Fibrotest (FT), Fibrosis Index (FI) and FIB-4 with different thresholds to predict presence or absence of fibrosis or cirrhosis in patients infected with

* Correspondence: sajihassan2004@yahoo.com
† Contributed equally
[1]Applied and Functional Genomics Lab, Centre of Excellence in Molecular Biology, University of the Punjab, Lahore-53700, Pakistan
Full list of author information is available at the end of the article

HCV had been proposed. However, mild fibrosis (F0) to end stage cirrhosis cannot be predicted accurately using a single system [9-18].

In this study, we compared and evaluated diagnostic accuracy of the readily available non-invasive serum indexes including AAR, APRI, FI and FIB-4 to find accurate and reliable non-invasive markers for evaluating fibrosis progression. We also developed a new non-invasive serum marker index for this purpose by evaluating several clinic-pathological features. A marker with high predictive values would eliminate the need of liver biopsy that also reduces the cost and risks associated to it.

Methods
Patients
This study was conducted at the Department of Pathology, Jinnah Hospital, Lahore; Mayo Hospital, Lahore and Liver Centre, Faisalabad in collaboration with Applied and Functional Genomics Lab, National Centre of Excellence in Molecular Biology (CEMB), University of the Punjab, Lahore, Pakistan. HCV RNA-positive patients were identified among HCV antibody (anti-HCV) positive patients. Later, the study plan was discussed with patients and the biopsy was taken only from those patients who were willing for this procedure. The purpose of this study was to design a new Index so that disease progression can be evaluated non-invasively and future need of biopsy can be eliminated. This was a retrospective cross-sectional study. This analytical study was carried out from March 2008 to September 2010.

Patients who received a previous course of INF or immunosuppressive therapy or who had clinical evidence of HBV or HIV and any type of liver cancer were excluded from the study. Patients who refused to have a liver biopsy or for whom it was contraindicated, i.e., because of a low platelet count, prolonged prothrombin time or decompensated cirrhosis were also excluded from the study. The liver biopsy procedure, its advantages and possible adverse effects were explained to the patients. Informed consent were obtained from patients contained information about demographic data, possible transmission route of HCV infection, clinical, virological and biochemical data. This study included 157 patients (M/F 114/43; mean age 38.1 ± 10.2, age range 19-58 years). The study was approved by Institutional Review Board (IRB, CEMB). The Federal-wide Assurance document (ID: FWA00001758) was approved by the local office for Human Research Protection.

Histological evaluation of biopsy samples
The histological evaluation of paraffin-embedded liver specimens was carried out at the Pathology Department, Jinnah Hospital, Lahore, according to METAVIR scoring system [19]. Liver biopsies were evaluated by two independent pathologists without prior information to patient's history. Histological staging based on the degree of fibrosis have five degrees of fibrosis: as F0 (no fibrosis), F1 (mild fibrosis without septa), F2 (moderate fibrosis with few septa), F3 (severe fibrosis with numerous septa without cirrhosis) and F4 (cirrhosis). We further grouped fibrosis stages as F0-F1 (minimal fibrosis), F2-F3 (advanced fibrosis), F4 (cirrhosis) and F2-F4 (significant fibrosis).

HCV RNA detection and quantitative PCR
RNA was extracted from 140 μl serum samples using QIAamp viral RNA extraction kit (Qiagen USA cat # 52906) according to the manufacturer's protocol. cDNA was synthesized using Moloney murine leukemia virus (MmLV) reverse transcriptase (Invitrogen, USA). First round and nested PCRs were carried out with Taq Polymerase (Fermentas USA) and analyzed on 2% agarose gel. Qiagen HCV quantitative kit was used to perform HCV RNA quantification with 10 ul of the extracted RNA on Roche Real Time PCR using fluorescent probes to detect amplification after each replicating cycle.

HCV genotyping
HCV genotyping was carried out using Invader HCV genotyping assay (Third wave technology USA). Briefly, about 100 ng of the HCV RNA was reverse transcribed to cDNA using 200U of MmLV (Invitrogen, USA). From the amplified product, 2 μl was taken and the genotyping assay was performed for 12 different HCV types.

Comparison of already available non-invasive serum biomarkers to evaluate patient's liver biopsy data
Serum samples and liver specimens collected from each patient were stored at -70°C for further biochemical analysis. The routine liver function tests (LFTs), Hb, serum albumin and direct bilirubin levels were anticipated for each patient. All biochemical tests and their scores were made without knowledge of liver biopsy results and all patients were evaluated for AAR, APRI, Fibrosis Index (FI) and FIB-4 indexes.

The following formulas were used to review the predicted scores with the particular cut-off values as mentioned previously.

- **AAR** [15] = AST (IU/l)/ ALT (IU/l)
  If AST/ALT ≥ 1, significant cirrhosis
- **APRI** [16] = [{AST (IU/l)/ ALT_ULN (IU/l)}× 100]/ platelet count (10^9/l)
  If APRI < 0.5, no or minimal fibrosis; if APRI > 1.5, significant fibrosis
- **FI** [17] = 8.0 - 0.01 × PLT (10^9/l) - serum albumin (g/dl)

If F-Index < 2.1, no or minimal fibrosis; F-index ≥ 2.1, significant fibrosis, and if F-Index ≥ 3.3, significant cirrhosis

- **FIB-4** [18] = [Age (Years) × AST (IU/l)]/[Platelet count (× 10^9/l) × ALT (IU/l)1/2]

  If FIB-4 < 1.45, no or minimal fibrosis, If FIB-4 > 3.25, significant fibrosis

Statistical analysis

The data was analyzed using statistical package SPSS version 16 for windows. A *p* value of 0.05 was considered statistically significant. All data was presented as mean values or no. of patients. Spearman's rank correlation was used to assess the significant association between continuous variables and liver fibrosis stages. The student *t*-test was used to compare arithmetic means and parameters while Chi-square ($X2$) test was used to compare categorical data, correlation with Fisher's exact test was used when appropriate. Patients were divided into three main groups as, patients with no or minimal fibrosis (F0-F1), patients with significant fibrosis (F2-F3) and patients with clinically significant cirrhosis (F4). The independently distinguished values of biochemical markers and AAR, APRI, FIB-4 and FI indexes for the prediction of significant fibrosis and cirrhosis were evaluated using univariate and multiple regression analysis. Area under the receiver operating characteristic (ROC) curves (AUROCs) was used to compare and deduce the diagnostic accuracies of the selected bio-markers.

Results

Patient's data

The demographic and clinical outcomes of the 157 HCV infected patients are briefly explained in Table 1. The evaluation of chronic HCV activity (inflammatory grade) showed mild chronic hepatitis in 51 patients, moderate chronic hepatitis in 67 patients and severe chronic hepatitis in 39 patients. The determination of liver fibrosis showed stage F0 in 29, F1 in 39, 34 patients in F2 and F3 stage each and 21 patients in F4 or advanced fibrosis leading to cirrhosis. Our data showed the presence of genotype 1a in 22 and 3a in 135 patients, 95 patients were < 40 years of age, while 62 were > 40 years of age.

Relationship between clinical findings and fibrosis

Liver fibrosis stages were statistically significant between age groups (*p*< 0.05). Mild and moderate fibrosis was diagnosed mostly in younger patients while more advanced stages were observed in patients over 40 years old. Patients with F0 fibrosis were too young as compared to those who developed moderate or severe

Table 1 Demographic, clinical, and liver histological features of 157 chronic HCV infected patients

Features	Mean (± SD)	Minimum	Maximum
Sex (Male/Female)	114/43	-	-
Age (years)	38.1 ± 10.2	19	58
Age groups (< 40/ > 40)	95/62	-	-
Genotype (1a/3a)	22/135	-	-
Viral load (IU/ml)	$5.47 \times 10^7 \pm 1.4 \times 10^8$	1.7×10^4	1.01×10^9
Hb level (g/dl)	12.7 ± 1.3	10.3	16.7
Bilirubin (mg/dl)	1.03 ± 0.36	0.5	2.1
ALT (IU/l)	134.4 ± 63.1	18	271
ALP (IU/l)	147.7 ± 101.5	20	438
AST (IU/l)	106.7 ± 68.2	20	395
Serum Albumin (g/dl)	4.1 ± 0.31	3.1	4.9
Platelet count (× 10^9/l)	154.5 ± 41.7	49	229
Liver fibrosis stages, n (%)			
F0	(n = 29, 18.5%)	-	-
F1	(n = 39, 24.8%)	-	-
F0+F1 (minimal fibrosis)	(n = 68, 43.3%)	-	-
F2	(n = 34, 21.7%)	-	-
F3	(n = 34, 21.7%)	-	-
F2+F3 (advanced fibrosis)	(n = 68, 43.3%)	-	-
F4 (Cirrhosis)	(n = 21, 13.4%)	-	-
F2+F3+F4 (significant fibrosis)	(n = 89, 56.7%)	-	-

fibrosis leading to cirrhosis (Mean age ± SD, 25.9 ± 2.4 years). The distribution of liver fibrosis stages with regard to gender and genotypes of patients illustrated in Table 2 showed no significant differences (for gender: *p = 0.247* and for genotypes: *p = 0.258*). Univariate analysis revealed that serum viral loads, bilirubin, albumin, platelet count, AST and ALP levels were significantly different in various fibrosis stages (Table 2).

Diagnosis of fibrosis using already available AAR, APRI, F-Index, and FIB-4 serum indexes

The relationship between the fibrosis stages and four serum indexes: AAR, APRI, FI and FIB-4 is illustrated in Figure 1 (see also Table 2). There was a significant relationship between fibrosis stages and serum indexes except AAR (*p* > 0.05). A gradual increase in the level of APRI, FI and FIB-4 indexes was observed in fibrosis stages.

The AUROCs of the serum non-invasive indexes scores are shown in Table 3. AUROC of FI was higher than APRI (*p*< 0.05) for differentiating minimal fibrosis from significant fibrosis (Figure 2). To predict cirrhosis, FI showed high AUROC than AAR. Spearman correlation between each serum index score and fibrosis stages was high for F-Index, FIB-4 and APRI, while, AAR showed significantly low 'r' index indicated in Table 3.

Table 2 Distribution of each variable according to fibrosis stages

Factor	F0 (n = 29)	F1(n = 39)	F2(n = 34)	F3(n = 34)	F4(n = 21)	*P* value
Age	25.9 ± 2.4	37.9 ± 9.5	42.8 ± 7.6	37.7 ± 8.5	48.4 ± 7.1	< 0.05
Sex (M/F)	19/10	35/4	26/8	20/14	14/7	0.247
Genotype (1a/3a)	8/21	4/35	3/31	3/31	4/17	0.258
HAI score	3.8 ± 2.1	6.05 ± 2.8	6.8 ± 3.2	6.9 ± 4.02	7.6 ± 2.9	< 0.05
Viral load	$6.2 \times 10^5 \pm 1.2 \times 10^6$	$1.3 \pm \times 10^7 \pm 1.5 \times 10^7$	$2.1 \times 10^8 \pm 2.4 \times 10^8$	$2.4 \times 10^7 \pm 2.5 \times 10^7$	$2.9 \times 10^5 \pm 2.9 \times 10^5$	< 0.05
Hb level	12.8 ± 1.3	12.6 ± 1.2	12.77 ± 1.7	12.9 ± 1.3	12.3 ± 1.2	0.328
Bilirubin	0.7 ± 0.1	0.88 ± 0.2	0.99 ± 0.27	1.2 ± 0.3	1.62 ± 0.31	< 0.05
ALT	120.2 ± 71.9	117.8 ± 55.3	152.1 ± 66.5	139.6 ± 56.6	147.5 ± 61.2	0.091
ALP	72.6 ± 16.8	88.1 ± 47.5	110.7 ± 45.1	208.6 ± 75.9	323.8 ± 80.1	< 0.05
AST	83.1 ± 57.9	107.1 ± 66.5	95.9 ± 51.4	106.9 ± 65.4	155.5 ± 90.6	< 0.05
Albumin	4.5 ± 0.1	4.3 ± 0.16	4.2 ± 0.18	4.08 ± 0.2	3.6 ± 0.33	< 0.05
Platelet count	191.3 ± 18.7	185.1 ± 21.2	162.1 ± 16.6	125.5 ± 18.7	81.6 ± 17.7	< 0.05
AAR	0.8 ± 0.58	1.14 ± 1.21	0.93 ± 1.1	1.02 ± 1.03	1.26 ± 0.95	0.522
APRI	1.04 ± 0.75	1.39 ± 0.87	1.40 ± 0.75	2.09 ± 1.33	4.7 ± 3.1	< 0.05
FI	1.24 ± 0.26	1.51 ± 0.28	1.81 ± 0.27	2.33 ± 0.28	3.2 ± 0.4	< 0.05
FIB-4	1.21 ± 0.95	2.17 ± 1.47	2.31 ± 1.57	3.06 ± 2.1	8.73 ± 6.59	< 0.05

By using published cut-off values for each index, we analyzed the sensitivity and specificity of each index for significant fibrosis and cirrhosis. Patients with minimal fibrosis can be identified from advanced/significant or cirrhotic patients using FIB-4, AAR, APRI and F-Index with sensitivity 51%, 67.6%, 19.1% and 100% and specificity 85.4%, 42.8%, 97.7% and 58.4%, respectively. At a cut-off value > 3.25 for FIB-4, > 1.5 for APRI, > 1 for AAR and > 3.3 for F-Index have 59.2%, 34.8%, 42.8% and 38.1% sensitivity and 82.3%, 67.6%, 67.6% and 100% specificity, respectively, to discriminate advanced fibrosis stages from minimal.

Figure 1 Box plots of the AAR, APRI, FIB-4 and FI for different fibrosis stages. The horizontal line inside each box represents the median, while the top and bottom of boxes represent the 25th and 75th percentiles, respectively. Vertical lines from the ends of the box encompass the extreme data points.

Diagnosis of fibrosis with clinic-pathological features including viral load, Hb level, bilirubin, ALT, ALP, AST, albumin and platelet count

Viral load was significant among fibrosis stages. It gradually increased in advanced fibrosis, and then suddenly dropped in cirrhosis. ALT and Hb levels were not significant, while AST levels were noteworthy to differentiate liver fibrosis stages. Meanwhile, only 16 (10.1%) and 21 (13.3%) patients showed normal ALT and AST levels, respectively, independent of fibrosis stage. The discriminative values of the biochemical markers for the prediction of different fibrosis stages were determined by logistic regression analysis. By univariate analysis ($p < 0.05$, Table 2), viral load, bilirubin, ALP, AST, albumin and platelet count were significantly associated with various fibrosis stages. However, in multivariate analysis, bilirubin, ALP, albumin and platelet count were found to be independently predictive (Table 4). This information related to these biochemical markers can also be helpful in differentiating liver fibrosis stages. Figure 3 shows the box plot of these four markers with liver histological stages. It is clear from Figure 3 and Table 2 that as the fibrosis increased, bilirubin and serum ALP level also increased, while platelet count and albumin level gradually reduced in cirrhosis. It was interesting to note that serum ALP and bilirubin was 2 times and 5 times higher in cirrhotic patients, respectively, than normal limits.

Based on ROC curve analysis as illustrated in Figure 4, four significant serum markers ALP, bilirubin, albumin and platelet count showed superior diagnostic power with high AUROCs for differentiating various fibrotic stages and cirrhosis as given in Table 5. Our data showed that if these four serum markers ALP, bilirubin,

Table 3 Validity of serum AAR, APRI, FIB-4 and FI in 157 HCV infected patients

| AAR							
Cutoff value	Spe%	Sen%	PPV%	NPV%	F0-F3 (n = 136)	F4 (n = 21)	AUC [95% CI]
< 1	42.8	67.6	88.4	16.9	92/44	12/9	0.468[0.377-0.559]
> 1	67.6	42.8	16.9	88.4	44/92	9/12	0.610[0.483-0.738]
APRI							
Cutoff value	Spe%	Sen%	PPV%	NPV%	F0-F1 (n = 68)	F2-F4 (n = 89)	AUC [95% CI]
< 0.5	97.7	19.1	86.6	61.2	13/55	2/87	0.715[0.635-0.795]
> 1.5	67.6	34.8	58.4	44.2	22/46	31/58	0.876[0.782-0.971]
FIB-4							
Cutoff value	Spe%	Sen%	PPV%	NPV%	F0-F2 (n = 102)	F3-F4 (n = 55)	AUC [95% CI]
< 1.45	85.4	51	86.6	48.4	52/50	8/47	0.732 [0.655-0.809]
> 3.25	82.3	59.2	64	79.2	18/84	33/22	0.545[0.456-0.635]
FI							
Cutoff value	Spe%	Sen%	PPV%	NPV%	F0-F1 (n = 68)	F2-F4 (n = 89)	AUC [95% CI]
< 2.1	58.4	100	64.7	100	68/0	37/52	0.939[0.903-0.974]
Cutoff value	Spe%	Sen%	PPV%	NPV%	F0-F3 (n = 136)	F4 (n = 21)	AUC [95% CI]
> 3.3	100	38.1	100	91.2	0/136	8/13	0.990[0.979-1.001]

Spearman rank correlation coefficient (R-index) for AAR = 0.130, APRI = 0.444, FIB-4 = 0.494 and FI = 0.578

albumin and platelet count are used simultaneously, they have high PPV and NPV for predicting cirrhosis and differentiating no/minimal fibrosis from significant fibrosis.

For the detection of significant cirrhosis, platelet count less than 100 showed 81% sensitivity, 98% specificity, 89% PPV and 97% NPV. For the same outcome, ALP > 240 IU/l had sensitivity, specificity, PPV and NPV of 90%, 92%, 60.7% and 97%, respectively. The bilirubin and albumin were also quite sensitive for the presence of cirrhosis. Bilirubin level > 1.5 had a sensitivity 66.6%, specificity 95.5%, PPV 70% and NPV 94%, while albumin < 3.85 g/dl has sensitivity, specificity, PPV and NPV 71.4%, 93%, 60% and 95%, respectively.

In no/minimal fibrosis, ALP < 120 IU/l showed sensitivity, specificity, PPV and NPV 85%, 70%, 68% and 86%, respectively. At cut-off value > 150, platelet count also showed high sensitivity (98%) and specificity (70%) with 71.2% PPV and 98% NPV. Serum bilirubin and albumin also showed same pattern with high sensitivity, specificity, PPV and NPV as shown in Table 5.

Construction of a new Index for the prediction of fibrosis stage

Based on the relationship of the regression coefficients of four-biochemical markers, ALP, bilirubin, albumin and platelet count, we developed a new fibrosis-cirrhosis index for the prediction of HCV disease progression from initial fibrosis stage to end stage cirrhosis.

Figure 2 Receiver operating characteristic curves generated by four serum markers, AAR, APRI, FIB-4 and FI for differentiation between patients in fibrosis stage F0-F1, F2-F3 and F4.

Table 4 Multivariate analysis of ALP, bilirubin, albumin and platelet count for discrimination between F0-F1 and F2-F3, and F2-F3 and F4 patients

Variables	F0-F1/F2-F3		F2-F3/F4	
	OR (95% CI)	P value	OR (95% CI)	P value
ALP	1.5 (105.13-51.34)	< 0.05	1.3 (203.25-124.93)	< 0.05
Bilirubin	2.1 (0.399- 0.122)	< 0.05	1.4 (0.719- 0.403)	< 0.05
Albumin	1.1 (0.126- 0.308)	< 0.05	1.3 (0.333- 0.598)	< 0.05
Platelet count	1.2 (34.71- 53.35)	< 0.05	1.2 (48.63- 75.72)	< 0.05

Figure 3 Relationship between fibrosis stages and the ALP, bilirubin, serum albumin and fibrosis-cirrhosis index (FCI). The lines through the middle of the boxes represent the median, while the top and bottom of the boxes are the 25th and 75th percentiles. The error bars represent measurement range (maximum and minimum values).

It can be represented as

$$FCI = \left[(ALP \times Bilirubin) / (Albumin \times Platelet\ count) \right]$$

The FCI distribution for the patients in the respective fibrosis stages is represented in Figure 5. The median values for FCI in F0-F1, F2-F3 and F4 patients were 0.085, 0.32 and 1.9, respectively. FCI significantly correlated with the liver fibrosis stages (Spearman's rank correlation coefficient, r = 0.818, $P< 0.05$). The diagnostic values of F1 to differentiate F0-F1 and F4 patients were evaluated using the AUROCs (Figure 6). The AUC for F0-F1 and F4 was 0.932 (CI: 0.895-0.969) and 0.996 (CI: 0.989-1.002), respectively. The cutoff values obtained from the respective ROC curves were < 0.130 and > ≥1.25 in discriminating F0-F1 and F4 patients, respectively. Table 5 illustrates the diagnostic accuracy of FCI. Using a cutoff value of < 0.130, FCI had a sensitivity of 81%, PPV of 82% also with a specificity of 87% and NPV

Figure 4 Receiver operating characteristic curves for individual serum markers; ALP, bilirubin, platelet count and serum albumin for the predication of F0-F1, F2-F3 and F4 fibrosis stages.

of 82% for the prediction of F0-F1. On the other hand, at a cutoff value of 1.25 or more, FCI had a sensitivity of 86%, specificity and PPV of 100% and 98% NPV for the prediction of cirrhosis (F4).

Discussion

Hepatocellular carcinoma and hepatic cirrhosis are consequences of chronic hepatitis C. The mean infection time to onset of cirrhosis is approximately 30 years, but cirrhosis may occur within a range of 10-50 years [20]. Fibrosis and its extension in hepatic tissue is most common evidence of cirrhosis. Several indexes are available to predict cirrhosis but no method or score is available on exclusive basis to diagnose earlier fibrosis stages.

Genotype 3a is the most common one followed by 1a in Pakistan [[3,21], and [22]] and same was also observed in this study. Almost, 86% patients had genotype 3a while remaining 14% had genotype 1a. A recent study also reported high prevalence of genotype 3 in HCC patients in Pakistan [23]. Patients with none or initial stage (F0-F1) of fibrosis showed a remarkable difference of age with advanced stages (F2 and F3) of fibrosis and cirrhosis. Most patients with age more than 40 years showed severe fibrosis and cirrhosis. These results confirmed the previous studies that patients with mild fibrosis stage were younger than the moderate and severe disease grade and stage is independent of gender [24-26].

Our results showed positive correlation of ALT with APRI and FI, and negative correlation with AAR and platelet, however, no correlation was established between ALT levels with disease severity and fibrosis stages. Our observation is in agreement with previous reports that serum ALT levels do not accurately predict the presence of hepatic liver damage [27,28]. Several authors reported persistently normal ALT levels (< 42 IU/l) in patients with chronic HCV. Almost, 30% of patients with chronic HCV infection reflect steadily normal serum ALT levels [29-32], however, in our data only 10% (n = 16) patients showed normal ALT levels.

Our data showed gradual increase in serum ALP and bilirubin levels (Table 2) in fibrosis stages when compared to early infection. Both ALP and bilirubin showed strapping significant correlation with disease progression. These results lead them to an important predictor of disease severity. An increased ALP is usually associated with liver metastasis, extrahepatic bile obstruction, intrahepatic cholestasis, infiltrative liver disease and hepatitis [33,34]. According to Lee *et al*, elevated serum ALP levels were common in liver abscess patients [35]. High bilirubin levels are associated with liver metastases and liver tumor involvement leading to hepatocellular carcinoma and liver cirrhosis by active or non-active HCV or HBV [36]. Limited literature is available on the role of

Table 5 Diagnostic accuracy of the ALP, bilirubin, albumin, platelet count and fibrosis-cirrhosis index (FCI) for the prediction of F0-F1 stage and hepatic cirrhosis in chronic HCV infected patients (n = 157)

Marker Cutoff	Interpretation		AUC [95% CI]	Spe%	Sen%	PPV%	NPV%
ALP							
< 120	F0-F1 (n = 68)	F2-F4 (n = 89)	0.829 [0.760-0.897]	69.6	85.2	68.2	86.1
	58/10	27/62					
> 240	F4 (n = 21)	F0-F3 (n = 136)	0.931 [0.882-0.981]	91.9	80.9	60.7	96.9
	17/4	11/125					
Bilirubin							
< 0.95	F0-F1 (n = 68)	F2-F4 (n = 89)	0.729 [0.643-0.815]	68.1	85.2	67.4	85.7
	58/10	28/60					
> 1.5	F4 (n = 21)	F0-F3 (n = 136)	0.889 [0.816-0.962]	95.5	66.6	70	94.8
	14/7	6/130					
Albumin							
> 4.1	F0-F1 (n = 68)	F2-F4 (n = 89)	0.812 [0.738-0.886]	67.4	100	70.1	100
	68/0	29/60					
< 3.85	F4 (n = 21)	F0-F3 (n = 136)	0.879 [0.796-0.962]	92.6	71.4	60	95.4
	15/6	10/126					
Platelet count							
> 150	F0-F1 (n = 68)	F2-F4 (n = 89)	0.935[0.900-0.970]	69.6	98.5	71.2	98.4
	67/1	27/62					
< 100	F4 (n = 21)	F0-F3 (n = 136)	0.990[0.977-1.002]	98.5	80.9	89.4	97.1
	17/4	2/134					
FCI							
< 0.130	F0-F1 (n = 68)	F2-F4 (n = 89)	0.932[0.895-0.969]	86.5	80.8	82.1	85.5
	55/13	12/77					
> 1.25	F4 (n = 21)	F0-F3 (n = 136)	0.996[0.989-1.002]	100	85.7	100	97.8
	18/3	0/136					

Spearman rank correlation coefficient (R-index) for ALP = 0.716, bilirubin = 0.597, albumin = -0.700, platelet count = -0.817 and FCI = 0.818.

elevated ALP and bilirubin levels in liver fibrosis stages. However, according to Imbert-Bismut *et al.* [37], bilirubin may be used as marker of liver injury, while a change in ALP levels greater than 120 U/L can be indicative of advanced disease progression [12]. These findings suggest that serum ALP and bilirubin may be used

Figure 5 Box plot of fibrosis-cirrhosis index (FCI) for each fibrosis stage. The horizontal line inside each box represents the median, while the top and bottom of boxes represent the 25th and 75th percentiles, respectively. Vertical lines from the ends of the box encompass the extreme data points.

Figure 6 Receiver operating characteristic curves generated by the fibrosis-cirrhosis index (FCI) to discriminate fibrosis stages F0-F1 and F4. FCI showed maximum AUC for prediction of F4 (cirrhosis).

as serum markers to assess the disease progression and fibrosis stages in chronic HCV patients.

Many studies supported that platelet count alone may be clinically valuable as a non-invasive serum marker for liver fibrosis and cirrhosis [38,39]. Platelets not only predict fibrosis but also correlate with fibrotic stages [40-42]. Lackner *et al*, [43] showed high AUROC of 0.89 for predicting cirrhosis at platelet value $< 150 \times 10^9$/L and AUROC of 0.71 for non-cirrhotic patients at a cutoff value $> 150 \times 10^9$/L. Our data is also in accordance with these results as platelet count showed high AUROC (≥ 0.900) to differentiate different liver fibrosis stages as given in Table 5 and Figure 4. In our study, platelet count was significantly low in cirrhotic patients. At a cutoff value of platelet, $< 100 \times 10^9$/L has an AUROC of 0.990 for prediction of cirrhosis with 81% sensitivity and 98% specificity. Ginnani *et al*, reported platelet $< 130 \times 10^9$/L for prediction of cirrhosis in HCV patients with 91.1% sensitivity, 88.3% specificity, PPV 81.2% and NPV 94.7% [44].

We also examined the ability of AAR, APRI, FIB-4 and F-Index for staging liver fibrosis and to differentiate them from cirrhosis. Giannini *et al*, reported a high diagnostic accuracy of AAR > 1.16 with 81.3% sensitivity and 55.3% specificity for the prediction of cirrhosis [44]. However, AAR was not able to differentiate among liver fibrosis stages in our sample data. At value of > 1.0, AAR has 43% sensitivity and 70% specificity for differentiating fibrosis from cirrhosis (Table 3). This poor performance of AAR is similar to that reported by Lackner *et al* [43].

We observed comparatively high APRI (1.24 ± 0.8) and FIB-4 (1.76 ± 1.35) values in F0-F1 patients. The group F0-F1 contains two subgroups, patients with no fibrosis (F0) and with minimal fibrosis (F1). The mean value of APRI and FIB-4 in F0 was 1.04 and 1.21, and in F1 1.39 and 2.17, respectively (Table 2). It is reported that APRI < 0.42 predict mild fibrosis and APRI > 1.2, significant fibrosis in HCV patients with 90% NPV for absence of fibrosis and 91% PPV for fibrosis presence [45-47]. Our results showed that APRI > 1.5 could predict fibrosis with 55% sensitivity, 67% specificity. Moreover, by using same cutoff value of APRI > 1.5 in a recent study by Macias *et al* [48], found that it has 28% sensitivity, 92% specificity, 79% PPV and 55% NPV for predicting significant fibrosis, and for absence of fibrosis APRI < 0.5 has 78%, 44%, 59% and 66% sensitivity, specificity, PPV and NPV, respectively.

FIB-4 was developed by Sterling *et al* in 2006 for diagnosis of fibrosis and cirrhosis in HIV/HCV co-infected patients. We examined this index only for HCV infected patients. A cutoff value of < 1.45 FIB-4 has a NPV for the exclusion of advanced fibrosis of 90%, while a cutoff value > 3.25 has a PPV for the diagnosis of extended fibrosis of 65% [49]. At a cutoff value of < 1.45, Vallet-Pichard observed a high NPV of 94.7% with a sensitivity of 74.3% to exclude severe fibrosis. Where as, for confirming the presence of advanced fibrosis at cutoff value > 3.25, FIB-4 had a PPV of 82.1% with specificity of 98.2% [18]. Our results are not in agreement with Sterling or Vallet-Pichard, as we observed a low NPV (70%) for excluding significant fibrosis, however, we detected a PPV of 83% with specificity of 45% for the presence of advanced fibrosis at cutoff value > 3.25. Trang *et al* [50], proposed new cutoff values of FIB-4 ≤ 1.39 for F0-F1 and ≥2.05 for F2-F4 stage in HCV/HIV co infected patients. At these cutoffs, we observed sensitivity 52%, specificity 76%, PPV 63% and NPV 68% for no/minimal fibrosis and 60%, 63%, 68% and 55% for advanced fibrosis, respectively. Although, we observed low statistical values, our results were in accordance to advance stage prediction. The cut off values proposed by Trang *et al* better predict fibrosis stages in co infected patients and we applied on only HCV infected patients.

Fibrosis index (FI) showed high sensitivity, specificity, PPV, NPV and AUROC for discriminating different fibrosis stages. Ohta developed this simple index in 2006. At cutoff value < 2.1 FI showed sensitivity and specificity for predicting F0-1 stage 66.8% and 78.8% in initial cohort and 68.5% and 63.6% in validation cohort, respectively [17]. At same cutoff, our data showed 100% sensitivity and 58.4% specificity with AUROC 0.939 for the prediction of none/minimal fibrosis. While for predicting cirrhosis in HCV patients, FI value > 3.30 has sensitivity and specificity 67.7% and 75% in initial cohort, and 70.8% and 81% in validation cohort, respectively. However, at this value we observed 33% sensitivity and 100% specificity for predicting cirrhosis (Table 3). We proposed that a new cutoff value of FI > 2.5 can better predict cirrhosis with 95.2% sensitivity and 94% specificity.

The readily available indexes are associated with some limitations like population discrepancy, not able to distinguish all fibrosis stages individually or some primarily developed for co-infected patients. So there is a need to develop a new index that can distinguish minimal fibrosis (F0-F1) from significant (F2-F4) and advanced (F2-F3) from cirrhosis (F4). While considering substantial relationship of routinely applied tests; serum ALP, ALT, AST, Hb level, bilirubin, albumin and platelet count with liver fibrosis stages, we found that four serum markers ALP, bilirubin, albumin and platelet count have high potential to differentiate different fibrosis stages and cirrhosis at given cutoff values (Table 5 and Figure 4). We also observed that combination of these serum markers could better differentiate among fibrosis stages with high sensitivity, specificity, PPV and NPV.

Our newly derived index FCI showed better performance for discriminating between fibrosis stages as compared to AAR, APRI and FI. In initial cohort, the AUROC for predicting F0-F1 stage for FCI was 0.932 when compared to recently used non-invasive serum markers like AAR (AUROC = 0.570) [15], APRI (AUROC = 0.880) [16], FI (AUROC = 0.741) [17], FIB-4 (AUROC = 0.793) [18], Forn's index (AUROC = 0.860) [51], and Fibrotest (AUROC = 0.870) [52]. Moreover, FCI (AUROC = 0.996) showed better performance for predicting cirrhosis than above mentioned serum indexes. Although in our study, platelet count showed high AUROC to predict fibrosis stages, systematic literature reviews consistently shown that panel of fibrosis markers are more accurate than single marker. Combination of two or more serum markers in a mathematical algorithm provide better chance of predicting phase of disease progression instead of individual one [37,53-57]. This analysis showed that FCI has tendency to reflect respective fibrosis stages from no/minimal to cirrhosis with great accuracy (Table 5, Figure 5 and 6). However, several studies are needed to verify these results. Secondly, because of poverty and fear of biopsy, we are not yet able to get enough patient data for verification of our FCI results in new cohort.

Conclusions

For Pakistani population the mostly used markers were failed to predict fibrosis stages in patients with HCV with accuracy. This study concluded that a simple index (FCI) containing ALP, bilirubin, albumin and platelet count may accurately classify different fibrosis stages from none to cirrhosis. Future studies are required to assess the applicability of this fibrosis-cirrhosis index within different populations and in patients with HBV or other fatty liver diseases.

Abbreviations
HCV: hepatitis C.

Author details
[1]Applied and Functional Genomics Lab, Centre of Excellence in Molecular Biology, University of the Punjab, Lahore-53700, Pakistan. [2]Fouzia Tahir Javed, Department of Pathology, Jinnah Hospital, Lahore-54590, Pakistan.

Authors' contributions
WA and BI contributed equally to this study. WA, BI and SH designed the study, analyze the data and wrote paper. JS, KS, PA, SA, SG, MTS and IS performed all lab work. FTJ and SA collected and arrange data. All work was performed under supervision of SH. All authors read and approved the final manuscript.

Authors' information
Bushra Ijaz (M Phil Molecular Biology), Waqar Ahmad (M Phil Chemistry), and Gull S (MSc Biochemistry) are Research Officer at CEMB. Shah Jahan, Saba Khaliq and Samrin A (PhD in Molecular biology), Javed FT is pathologist at Jinnah hospital Lahore. Sarwar MT, Kausar H, Asad S and Shahid I are PhD scholars; while Sajida Hassan (PhD Molecular Biology) is Principal Investigator at CEMB, University of the Punjab, Lahore.

References
1. Giannini C, Brechot C: **Hepatitis C virus biology.** *J Virology* 2003, **10**: S27-S38.
2. Alter MJ: **Epidemiology of hepatitis C.** *Hepatology* 1997, **26**:62S-65S.
3. Raja NS, Janjua KA: **Epidemiology of hepatitis C virus infection in Pakistan.** *J Microbiol Immunol Infect* 2008, **41**:4-8.
4. Idrees M, Riazuddin S: **Frequency distribution of hepatitis C virus genotypes in different geographical regions of Pakistan and their possible routes of transmission.** *BMC Infect Dis* 2008, **8**:69.
5. EL-Serag HB: **Hepatocellular carcinoma and hepatitis C in the United States.** *Hepatology* 2002, **36**:S74-S83.
6. Moriya K, Fujie H, Shintani Y, Yotsuyanagi H, Tsutsumi T, Ishibashi K, Matsuura Y, Kimura S, Miyamura T, Kpike K: **The Core protein of hepatitis C virus induces hepatocellular carcinoma in transgenic mice.** *Nat Med* 1998, **4**:1065-1077.
7. Adinolfi LE, Gambardella M, Andreana A, Tripodi MF, Utili R, Ruggiero G: **Steatosis accelerates the progression of liver damage of chronic hepatitis C patients and correlates with specific HCV genotype and visceral obesity.** *Hepatology* 2001, **33**:1358-1364.
8. National Institute of health Consensus Development Conference Statement: **Management of Hepatitis C: 2002.** *Hepatology* 2002, **36**:973-977.
9. Silva RG Jr, Fakhouri R, Nascimento TV, Santos IM, Barbosa LM: **Aspartate aminotransferase-to-Platelet ration index for fibrosis and cirrhosis prediction in chronic hepatitis C patients.** *Braz J Infect Dis* 2008, **12**:15-19.
10. Pratt DS, Kaplan MM: **Evaluation of abnormal liver-enzyme results in asymptomatic patients.** *N Eng J Med* 2000, **342**:1266-1271.
11. Parise ER, Oliveira AC, Figueiredo-Mendes C, Lanzoni V, Martins J, Nader H, Ferraz ML: **Noninvasive serum markers in the diagnosis of structural liver damage in chronic hepatitis C virus infection.** *Liver Int* 2006, **26**:1095-1099.
12. Azzari C, Resti M, Moriondo M, Ferrari R, Lionetti P, Vierucci A: **Vertical transmission of HCV is related to maternal peripheral blood mononucleat cell infection.** *Blood* 2000, **96**:2045-2048.
13. Kowala-Piaskowska A, Mozer-Lisewska I, Figlerowicz M, Sluzewski W: **Influence of the presence of HCV-RNA in peripheral blood mononuclear cells on the clinical course of chronic hepatitis C in children.** *Eur J Epidemiol* 2007, **22**:343-348.
14. Castera L, Pinzani M: **Non-invasive assessment of liver fibrosis: are we ready.** *Lancet* 2010, **375**:1419-1420.
15. Hoofnagle JH, Williams AL: **Ratio of serum aspartate to alanine aminotransferase in chronic hepatitis: relationship to cirrhosis.** *Gastroenterology* 1988, **95**:734-739.
16. Wai CT, Greenson JK, Fontana RJ, Kalbfleisch JD, Marrero JA, Conjeevaram HS, Lok AS: **A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C.** *Hepatology* 2003, **38**:518-526.
17. Ohta T, Sakaguchi K, Fujiwara A, Fujioka S, Iwasaki Y, makino Y, Araki Y, Shiratori Y: **Simple surrogate index of the fibrosis stage in chronic hepatitis C patients using platelet count and serum albumin level.** *Acta Med Okayama* 2006, **60**:77-84.
18. Vallet-Pichard A, Mallet V, Nalpas B, Verkarre V, Nalpas A, Dhalluin-Venier V, Fontaine H, Pol S: **FIB-4: an inexpensive and accurate marker of fibrosis in HCV infection. Comparison with liver biopsy and FibroTest.** *Hepatology* 2007, **46**:32-36.
19. The French METAVIR Cooperative Study Group: **Intraobserver and interobserver variations in liver biopsy interpretation in patients with chronic hepatitis C.** *Hepatology* 1994, **20**:15-20.
20. Poynard T, Bedossa P, Opolon P: **Natural history of liver history of liver fibrosis progression in Patients with chronic hepatitis C. The OBVIRC, METAVIR, CLINIVIR, and DOSVIRC groups.** *Lancet* 1997, **349**:825-832.

21. Ahmad W, Ijaz B, Javed FT, Jahan S, Shahid I, Khan FM, Hassan S: **HCV genotype distribution and possible transmission risks in Lahore, Pakistan.** *World J Gastroenterology* 2010, **16**:4321-4328.
22. Kobayashi M, Tanaka E, Sodeyama T, Urushihara A, Matsumoto A, Kiyosawa K: **The natural course of chronic hepatitis C: a comparison between patients with genotypes 1 and 2 hepatitis C viruses.** *Hepatology* 1996, **23**:695-699.
23. Idrees M, Rafique S, Irshad-ur-rehman , Akbar H, Yousaf MZ, Butt S, Awan Z, Manzoor S, akram M, Aftab M, Khubaib B, Riazuddin S: **Hepatitis C genotype 3a infection and hepatocellular carcinoma: Pakistan experience.** *World J Gasteroenterol* 2009, **15**:5080-5085.
24. Mendes SCL, Nita EM, Ono-Nita KS, Mello SE, Silva CL, Alves VA, Carriho FJ: **Prognostic factors for progression of liver structural lesions in chronic hepatitis C patients.** *World J Gastroenterol* 2008, **14**:2522-2528.
25. Tassopoulos NC, Papatheodoridis GV, Katsoulidou A, Delladetsima JK, Sypsa V, Touloumi G, Nikandros M, Hatzakis A: **Factors associated with severity and disease progression in chronic hepatitis C.** *Hepatogastroenterology* 1998, **45**:1678-1683.
26. Ramalho F, Costa A, Pires A, Cabrita P, Sereojo F, Correia AP, Fatela N, Cloria H, Lopes J, Pinto HC, Marinho R, Raimundo M, Velosa J, Batista A, de Moura MC: **Correlation of genotypes and route of transmission with histologic activity and disease stage in chronic hepatitis C.** *Dig Dis Sci* 2000, **45**:182-187.
27. Puoti C, Magrini A, Stati T, Rigato P, Montagnese F, Rossi P, Aldegheri L, Resta S: **Clinical, histological, and virological features of hepatitis C virus carriers with persistently normal or abnormal alanine transaminase levels.** *Hepatology* 1997, **26**:1393-1398.
28. Haber MM, West AB, Haber AD, Reuben A: **Relationship of aminotransferases to liver histological status in chronic hepatitis C.** *Am J Gastroenterol* 1995, **90**:1250-1257.
29. Bacon BR: **Treatment of patients with hepatitis C and normal serum aminotransferase levels.** *Hepatology* 2002, **32**:634-643.
30. Moatter T, Hussainy AS, Hamid S, Ahmad Z, Siddiqui S: **Comparative analysis of viral titers and histologic features of Pakistani patients infected with hepatitis C virus type 3.** *Int J Infect Dis* 2002, **6**:272-276.
31. Shafique M, Ahmad N, Awan FR, Mustafa T, Ullah M, Qureshi JA: **Investigating the concurrent presence of HCV in serum, oral fluid and urine samples from chronic HCV patients in Faisalabad, Pakistan.** *Arch Virol* 2009, **154**:1523-1527.
32. Mastoi AA, Devrajani BR, Shah SZA, Rohopoto Q, Memon SA, Baloch M, Qureshi GA, Sami W: **Metabolic investigations in patients with hepatitis B and C.** *World J Gastroenterol* 2010, **16**:603-607.
33. Viroj W: **High serum alkaline phosphatase levels, a study in 181 Thai adult hospitalized patients.** *BMC Family Practice* 2001, **2**:2.
34. Saif MW, Alexander D, Wicox CM: **Serum Alkaline Phosphatase Level as Prognostic Tool in Colorectal Cancer: A study of 105 patients.** *J Appl Res* 2005, **5**:88-95.
35. Lee GH, Benner D, Regidor DL, Kalatar-Zadeh K: **Impact of kidney bone disease and its management on survival of patients on dialysis.** *J Ren Nutr* 2007, **17**:38-44.
36. Raymond E, Boige V, Faivre S, Sanderink G, Rixe O, Vernillet L, Jacques C, Gatineau M, Ducreux M, Armand JP: **Dosage adjustment and pharmacokinetic profile of Irinotecan in cancer patients with hepatic dysfunction.** *J Clin Oncol* 2002, **20**:4303-4312.
37. Imbert-Bismut F, Ratziu V, Pieroni L, Charlotte F, Benhamou Y, Poynard T: **Biochemical markers of liver fibrosis in patients with hepatitis C virus infection: a prospective study.** *Lancet* 2001, **357**:1069-1075.
38. Myres RP, De Torres M, Imbert-Bismut F, Ratziu V, Charlotte F, Poynard T, MULTIVIRC Group: **Biochemical markers of fibrosis in patients with chronic hepatitis C: a comparison with prothrombin time, platelet count, and age-platelet index.** *Dig Dis Sci* 2003, **48**:271-278.
39. Ghany MG, Lok AS, Everhart JE, Everson GT, Lee WM, Cuto TM, Wright EC, Stoddard AM, Sterling RK, Di Bisceglie AM, Bonkovsky HL, Morishima C, Morgan TR, Dienstag JL, HALT-C Trial Group: **Predicting clinical and histologic outcomes based on standard laboratory tests in advanced chronic hepatitis C.** *Gasteroenterology* 2010, **138**:136-146.
40. Murawaki Y, Koda M, Okamoto K, Mimura K, Kawasaki H: **Diagnostic value of serum type IV collagen test in comparison with platelet count for predicting the fibrotic stage in patients with chronic hepatitis.** *J Gastrentrol Hepatol* 2001, **16**:777-781.
41. Pohl A, Behling C, Oliver D, Kilani M, Monson P, Hassanein T: **Serum aminotransferase levels and platelet counts as predictors of degree of fibrosis in chronic hepatitis C virus infection.** *Am J Gastroenterol* 2001, **96**:3053-3055.
42. Fusegawa H, Shiraishi K, Ogasawara F, Shimizu M, Haruki Y, Miyachi H, Matsuzaki S, Ando Y: **Platelet activation in patients with chronic hepatitis C.** *Tokai J Exp Clin Med* 2002, **27**:101-106.
43. Lackner C, Struber G, Liegl B, Leibl S, Ofner P, Bankuti C, Bauer B, Stauber RE: **Comparison and validation of simple noninvasive tests for prediction of fibrosis in chronic hepatitis C.** *Hepatology* 2005, **41**:1376-1382.
44. Giannini E, Risso D, Botta F, Chiarbonello B, Fasoli A, Malfatti F, Romagnoli P, testa E, Ceppa P, Testa R: **Validity and clinical utility of the aspartate aminotransferase-alanine aminotransferase ration in assessing disease severity and prognosis in patients with hepatitis C virus related chronic liver disease.** *Arch Intern Med* 2003, **163**:218-224.
45. Shaikh S, Memon MS, Ghani H, Baloch GH, Jaffery M, Shaikh K: **Validation of Three Non-Invasive Markers in Assessing the Severity of Liver Fibrosis in Chronic Hepatitis C.** *JCPSP* 2009, **19**:478-482.
46. Khan DA, Fatima-Tuz-Zuhra , Khan FA, Mubarak A: **Evaluation of diagnostic accuracy of apri for prediction of fibrosis in hepatitis c patients.** *J Ayub Med Coll Abbottabad* 2008, **20**:122-126.
47. Snyder N, Gajula L, Xiao SY, Grady J, Luxon B, Lau DT, Soloway R, Petersen J: **APRI: an easy and validated predictor of hepatic fibrosis in chronic hepatitis C.** *J Clin Gastroenterol* 2006, **40**:535-542.
48. Macias J, Gonzalez J, Ortega E, Tural C, Cabrero E, Burgos A, Pineda JA, GRAFIHCO Study Team: **Use of simple noninvasive biomarkers to predict liver fibrosis in HIV/HCV coinfection in routine clinical practice.** *HIV Med* 2010, **11**:439-447.
49. Sterling RK, Lissen E, Clumeck N, Sola R, Correa MC, Montaner J, Sulkowski SM, Torriani FJ, Dieterich DT, Thomas DL, Messinger D, Nelson M, APRICOT Clinical Investigators: **Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection.** *Hepatology* 2006, **43**:1317-1325.
50. Trang T, Petersen JR, Snyder N: **Non-invasive markers of hepatic fibrosis in patients co-infected with HCV and HIV: Comparison of the APRI and FIB-4 index.** *Clinica Chimica Acta* 2008, **397**:51-54.
51. Forns X, Ampurdanes S, Liovet JM, Aponte J, Quinto L, Marteniz-Bauer E, Bruguera M, Sanchez-Tapias JM, Rodes J: **Identification of chronic hepatitis C patients without hepatic fibrosis by a simple predictive model.** *Hepatology* 2003, **36**:986-992.
52. Myers RP, Ratziu V, Imbert-Bismut F, Charlotte F, Poynard T, MULTIVIRIC Group: **Biochemical markers of liver fibrosis: a comparison with histological features in patients with chronic hepatitis C.** *Am J Gasteroenterol* 2002, **97**:2419-2425.
53. Guha IN, Parkes J, Roderick PR, Harris S, Rosenberg WM: **Non-invasive markers associated with liver fibrosis in non-alcoholic fatty liver disease 2.** *GUT* 2006, **55**:1650-1660.
54. Parkes J, Guha IN, Roderick P, Rosenberg W: **Performance of serum marker panels for liver fibrosis in chronic hepatitis C.** *J Hepatology* 2006, **44**:462-474.
55. Pinzani M: **The ELF panel: a new crystal ball in hepatology?** *Gut* 2010, **59**:1165-1167.
56. Wang M, Long RE, Comunale MA, Junaidi O, Marrero J, Di Bisceglie AM, Block TM, Mehta AS: **Novel Fucosylated Biomarkers for the Early Detection of Hepatocellular Carcinoma.** *Cancer Epidemiol Biomarkers Prev* 2009, **18**:1914-1921.
57. Rosenberg WM, Voelker M, Thiel R, Becka M, Burt A, Schuppan D, Hubscher S, Roskams T, Pinzani M, Arthur MJ: **European Liver Fibrosis Group: Serum markers detect the presence of liver fibrosis: a cohort study.** *Gastroenterology* 2004, **127(6)**:1704-1713.

Pre-publication history